In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Zealand Pharma licenses Aventis rights to diabetes compound

Executive Summary

Biopharmaceutical company Zealand Pharma AS (therapeutics for diabetes, cardiac arrhythmia, and heart failure) licensed Aventis worldwide rights to its lead compound ZP10, a glucagon-like peptide-1 (GLP-1) receptor agonist in Phase I/IIa clinical trials to treat Type II diabetes.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies